AU2014312119B2 - Administration of kynurenine depleting enzymes for tumor therapy - Google Patents

Administration of kynurenine depleting enzymes for tumor therapy Download PDF

Info

Publication number
AU2014312119B2
AU2014312119B2 AU2014312119A AU2014312119A AU2014312119B2 AU 2014312119 B2 AU2014312119 B2 AU 2014312119B2 AU 2014312119 A AU2014312119 A AU 2014312119A AU 2014312119 A AU2014312119 A AU 2014312119A AU 2014312119 B2 AU2014312119 B2 AU 2014312119B2
Authority
AU
Australia
Prior art keywords
kynureninase
cell
enzyme
tumor
kynurenine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014312119A
Other languages
English (en)
Other versions
AU2014312119A1 (en
Inventor
George Georgiou
Everett Stone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2014312119A1 publication Critical patent/AU2014312119A1/en
Application granted granted Critical
Publication of AU2014312119B2 publication Critical patent/AU2014312119B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y307/00—Hydrolases acting on carbon-carbon bonds (3.7)
    • C12Y307/01—Hydrolases acting on carbon-carbon bonds (3.7) in ketonic substances (3.7.1)
    • C12Y307/01003—Kynureninase (3.7.1.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2014312119A 2013-08-30 2014-08-29 Administration of kynurenine depleting enzymes for tumor therapy Active AU2014312119B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361872132P 2013-08-30 2013-08-30
US61/872,132 2013-08-30
US201461986366P 2014-04-30 2014-04-30
US61/986,366 2014-04-30
PCT/US2014/053437 WO2015031771A2 (en) 2013-08-30 2014-08-29 Administration of kynurenine depleting enzymes for tumor therapy

Publications (2)

Publication Number Publication Date
AU2014312119A1 AU2014312119A1 (en) 2016-03-17
AU2014312119B2 true AU2014312119B2 (en) 2019-09-19

Family

ID=52583559

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014312119A Active AU2014312119B2 (en) 2013-08-30 2014-08-29 Administration of kynurenine depleting enzymes for tumor therapy

Country Status (12)

Country Link
US (5) US9808486B2 (enExample)
EP (2) EP3492094A1 (enExample)
JP (4) JP6307163B2 (enExample)
KR (2) KR102271498B1 (enExample)
CN (2) CN105722522B (enExample)
AU (1) AU2014312119B2 (enExample)
BR (1) BR112016004095A2 (enExample)
CA (2) CA2922670C (enExample)
ES (1) ES2707711T3 (enExample)
IL (2) IL244312B (enExample)
WO (1) WO2015031771A2 (enExample)
ZA (1) ZA201601443B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150320799A1 (en) 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP3492094A1 (en) 2013-08-30 2019-06-05 Board of Regents, The University of Texas System Administration of kynurenine depleting enzymes for tumor therapy
EP3186371B1 (en) * 2014-08-29 2024-08-14 Board of Regents, The University of Texas System Administration of kynurenine depleting enzymes for tumor therapy
EP3207130B1 (en) 2014-10-14 2019-08-07 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CA2984624A1 (en) * 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
US11723932B2 (en) 2016-01-11 2023-08-15 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
WO2017151860A1 (en) 2016-03-02 2017-09-08 Broard Of Regents, The University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
KR20190084053A (ko) 2016-10-13 2019-07-15 주노 쎄러퓨티크스 인코퍼레이티드 트립토판 대사 경로 조절인자 관련 면역 치료 방법 및 조성물
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
EP3651782A1 (en) * 2017-07-12 2020-05-20 Synlogic Operating Company, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
WO2019089740A1 (en) * 2017-11-03 2019-05-09 Dana-Farber Cancer Institute, Inc. Biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
AU2019209432A1 (en) 2018-01-22 2020-08-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for CAR T cells
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
JP7432851B2 (ja) * 2018-04-16 2024-02-19 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ヒトキヌレニナーゼ酵素及びその使用
CN110412179A (zh) * 2018-04-26 2019-11-05 缪荣明 一种液相色谱检测颗粒酶a的方法
US20220056407A1 (en) * 2018-12-14 2022-02-24 Autolus Limited Cell
WO2021076966A1 (en) * 2019-10-17 2021-04-22 Ikena Oncology, Inc. Pegylated kynureninase enzymes and uses thereof for the treatment of cancer
JPWO2023229024A1 (enExample) * 2022-05-27 2023-11-30
WO2024085280A1 (ko) * 2022-10-20 2024-04-25 서울대학교 산학협력단 신규한 키뉴레니나제 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012099441A2 (ko) * 2011-01-21 2012-07-26 인제대학교산학협력단 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030194721A1 (en) 2001-09-19 2003-10-16 Incyte Genomics, Inc. Genes expressed in treated foam cells
EP1470240A4 (en) 2002-02-01 2006-08-30 Millennium Pharm Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES USING 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419 , 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2
CN1330774C (zh) * 2002-03-01 2007-08-08 国家人类基因组南方研究中心 犬尿氨酸水解酶多态性及其用途
CA2520586C (en) 2003-03-27 2011-06-14 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
US20070207158A1 (en) 2003-06-17 2007-09-06 Harrison Roger G Conjugate for the specific targeting of anticancer agents to tumor cells or tumor vasculature and production thereof
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
JP2008237022A (ja) 2005-06-30 2008-10-09 Osaka Prefecture 非小細胞肺がんの予防・治療剤および診断薬
JP5319532B2 (ja) * 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
GB0625310D0 (en) * 2006-12-19 2007-01-24 Bioalvo Yeast platform construction and screening methods
EP2483301A1 (en) 2009-10-01 2012-08-08 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
US9212229B2 (en) 2010-09-08 2015-12-15 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Chimeric antigen receptors with an optimized hinge region
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20120085209A (ko) * 2011-01-21 2012-07-31 인제대학교 산학협력단 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물
US9593062B2 (en) * 2011-09-07 2017-03-14 Deutschland Krebsforschungszentrum Means and methods for treating and/or preventing natural AHR ligand-dependent cancer
WO2013059593A1 (en) 2011-10-20 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd22 chimeric antigen receptors
EP3492094A1 (en) 2013-08-30 2019-06-05 Board of Regents, The University of Texas System Administration of kynurenine depleting enzymes for tumor therapy
EP3186371B1 (en) 2014-08-29 2024-08-14 Board of Regents, The University of Texas System Administration of kynurenine depleting enzymes for tumor therapy
WO2017151860A1 (en) 2016-03-02 2017-09-08 Broard Of Regents, The University Of Texas System Human kynureninase enzyme variants having improved pharmacological properties
JP6912171B2 (ja) * 2016-09-15 2021-07-28 株式会社トプコン 眼科検査装置
JP7432851B2 (ja) 2018-04-16 2024-02-19 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ヒトキヌレニナーゼ酵素及びその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012099441A2 (ko) * 2011-01-21 2012-07-26 인제대학교산학협력단 트립토판 대사효소 유전자를 발현하는 줄기세포를 함유하는 면역 반응 억제용 조성물

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
J. GODIN-ETHIER ET AL, "Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives", CLINICAL CANCER RESEARCH, US, (2011-11-08), vol. 17, no. 22, pages 6985 - 6991 *
RUTELLA S ET AL, "Targeting indoleamine 2,3-dioxygenase (IDO) to counteract tumour-induced immune dysfunction: from biochemistry to clinical development", ENDOCRINE, METABOLIC & IMMUNE DISORDERS - DRUG TARGETS, vol. 9, no. 2, p. 151 - 177 *
S. TOMA ET AL, "Cloning and recombinant expression of rat and human kynureninase", FEBS LETTERS, (1997-05-12), vol. 408, no. 1, ISSN 0014-5793, pages 5 - 10 *
SANTIAGO LIMA ET AL, "Crystal Structure of Homo sapiens Kynureninase", BIOCHEMISTRY, US, (2007-03-01), vol. 46, no. 10, doi:10.1021/bi0616697, ISSN 0006-2960, pages 2735 - 2744 *
YVETTE MÃ NDI ET AL, "The kynurenine system and immunoregulation", JOURNAL OF NEURAL TRANSMISSION, (2011-07-09), vol. 119, no. 2, pages 197 - 209. *

Also Published As

Publication number Publication date
US10772913B2 (en) 2020-09-15
CA2922670A1 (en) 2015-03-05
EP3038636A2 (en) 2016-07-06
ES2707711T3 (es) 2019-04-04
JP7029316B2 (ja) 2022-03-03
NZ717492A (en) 2021-10-29
JP2018127463A (ja) 2018-08-16
CN113957061A (zh) 2022-01-21
KR102442231B1 (ko) 2022-09-13
US20240091258A1 (en) 2024-03-21
JP2022159570A (ja) 2022-10-17
EP3038636B1 (en) 2018-11-07
CA3173052A1 (en) 2015-03-05
US9808486B2 (en) 2017-11-07
IL244312B (en) 2019-03-31
JP2020111611A (ja) 2020-07-27
EP3492094A1 (en) 2019-06-05
BR112016004095A2 (pt) 2017-10-17
AU2014312119A1 (en) 2016-03-17
CN105722522A (zh) 2016-06-29
WO2015031771A3 (en) 2015-05-14
KR20210082264A (ko) 2021-07-02
IL264901B (en) 2019-08-29
US20210213059A1 (en) 2021-07-15
KR20160048971A (ko) 2016-05-04
JP6307163B2 (ja) 2018-04-04
US11534463B2 (en) 2022-12-27
IL244312A0 (en) 2016-04-21
KR102271498B1 (ko) 2021-07-05
CN105722522B (zh) 2021-10-19
EP3038636A4 (en) 2017-04-26
US20200054674A1 (en) 2020-02-20
ZA201601443B (en) 2019-08-28
US20150064154A1 (en) 2015-03-05
WO2015031771A2 (en) 2015-03-05
CA2922670C (en) 2022-11-29
US20170056449A1 (en) 2017-03-02
JP2016533753A (ja) 2016-11-04

Similar Documents

Publication Publication Date Title
US11534463B2 (en) Nucleic acids encoding kynurenine depleting enzymes
US11168142B2 (en) Administration of kynurenine depleting enzymes for tumor therapy
AU2014312168B2 (en) Engineered primate cystine/cysteine degrading enzymes as antineogenic agents
US20230227796A1 (en) Enzyme-mediated depletion of adenosine and/or methylthioadenosine
HK1226335A1 (en) Administration of kynurenine depleting enzymes for tumor therapy
HK1226335B (en) Administration of kynurenine depleting enzymes for tumor therapy
NZ717492B2 (en) Administration of kynurenine depleting enzymes for tumor therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)